COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF GLYPICAN-3 (GPC3)-EXPRESSING TUMORS

Technology
E-108-2021
Patent ID
E-108-2021-0-US-01
Country
US
Application Type
 
Patent Status
Abandoned
Patent Number
 
Publication Number
 
Application Number
63/196,556
IC
NCI
Date Filed
Date Issued
 
Patent PDF
 
Related Technologies
TAB-4196     Combination of recombinant IL-7 with Chimeric Antigen Receptor (CAR) T Cells Targeting Glypican-3 (GPC3) for the Treatment of Hepatocellular Carcinoma (HCC)